Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.850
-0.040 (-2.12%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.090 (4.86%)
After-hours: Apr 28, 2026, 7:45 PM EDT
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$4,122,028
Market Cap
63.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| MindWalk Holdings | 102 |
| OnKure Therapeutics | 45 |
| Cue Biopharma | 29 |
| MiNK Therapeutics | 23 |
| iBio, Inc. | 20 |
| Edesa Biotech | 17 |
| ImageneBio | 15 |
ANVS News
- 13 hours ago - Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - GlobeNewsWire
- 18 days ago - Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - GlobeNewsWire
- 19 days ago - Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - GlobeNewsWire
- 26 days ago - Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - GlobeNewsWire
- 4 weeks ago - Annovis Publishes Historical Review of Buntanetap in The Scientist - GlobeNewsWire
- 5 weeks ago - Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - GlobeNewsWire
- 5 weeks ago - NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - GlobeNewsWire
- 6 weeks ago - Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - GlobeNewsWire